Results 201 to 209 of about 19,727 (209)
Some of the next articles are maybe not open access.

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

Gut, 2016
Kerstin Herzer   +2 more
exaly  

Sofosbuvir/velpatasvir

Reactions Weekly, 2021
openaire   +1 more source

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

Hepatology, 2015
Eric Lawitz   +2 more
exaly  

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

New England Journal of Medicine, 2015
Susanna Naggie   +2 more
exaly  

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

New England Journal of Medicine, 2013
exaly  

Prices of sofosbuvir and ledipasvir/sofosbuvir unaffordable

PharmacoEconomics & Outcomes News, 2016
openaire   +1 more source

Daclatasvir/sofosbuvir

Reactions Weekly, 2017
openaire   +1 more source

Ribavirin/sofosbuvir

Reactions Weekly, 2017
openaire   +1 more source

Sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir

Reactions Weekly
openaire   +1 more source
daclatasvir
hepatitis c
medicine
hcv
chronic hepatitis c
direct-acting antiviral
velpatasvir
ledipasvir
hepatitis c, chronic
previous   19  20  21  

Home - About - Disclaimer - Privacy